ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer (ARMOR1)

Clinical Trial ID NCT00959959

Rank	Title	Journal	Year	PubWeight™‹?›
1	New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.	Clin Cancer Res	2011	2.01
2	Drug resistance in metastatic castration-resistant prostate cancer.	Nat Rev Clin Oncol	2010	1.86
3	Androgen action and metabolism in prostate cancer.	Mol Cell Endocrinol	2012	1.25
4	Androgen receptor antagonists in castration-resistant prostate cancer.	Cancer J	2013	1.19
5	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.	Prostate Cancer Prostatic Dis	2011	0.93
6	Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.	Curr Oncol	2012	0.89
7	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.	Int J Mol Sci	2013	0.88
8	Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.	Asian J Androl	2014	0.86
9	Emerging molecularly targeted therapies in castration refractory prostate cancer.	Prostate Cancer	2013	0.83
10	New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer.	Prostate Cancer	2011	0.79
11	Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer.	Front Endocrinol (Lausanne)	2012	0.76
12	Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.	Clin Genitourin Cancer	2014	0.75